IL-1β centrality via canakinumab trial
de Koning HD, et al.
Arthritis Res Ther · 2015
Key Findings
- ●IL-1β centrality demonstrated
- ●PBMCs hyperresponsive to LPS
Referenced in (1 disease)
Validation history
Full log →No validation events recorded yet. Source will be checked on the next kipine-source-validator run.
ID: pmid-26198339DOI: 10.1186/s13075-015-0709-6PMID: 26198339